

# The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study

NCT05489588

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	W.L.Gore & Associates
Enrollment	165 participants

## Key Eligibility Criteria

---

### Inclusion (17)

- Patient is at least 18 years of age.
- Patient is willing and able to comply with all follow-up evaluations as well as any required medication or compression regimen.
- Patient is able to provide informed consent.
- One of the following: Clinical severity class of CEAP 'C' classification e3 or rVCSS pain score e2.
- Intention to treat the target areas with only the GORE® VIAFORT Vascular Stent.

... and 12 more (see full listing online)

### Exclusion (24)

- Patient has DVT in the target areas with symptom onset date greater than 14 days but less than or equal to 90 days prior to treatment.
- Patient is a pregnant or breastfeeding woman, or a woman planning to become pregnant through the 12-month visit.
- Patient has clinically significant (e.g., symptoms of chest pain, hemoptysis, dyspnea, hypoxia, etc.) pulmonary embolism (confirmed via Computed Tomography Angiography) at the time of enrollment.
- Patient has a known uncorrectable bleeding diathesis or active coagulopathy meeting the following definitions (all must be tested for):
- uncorrected INR > 2 (not as a result of warfarin or DOAC therapy), OR

... and 19 more (see full listing online)

## Locations (27 total)

---

Stanford University School of Medicine, Stanford, California, United States  
Advanced Heart and Vein (ClinRe), Thornton, Colorado, United States  
Vascular Care Group, Darien, Connecticut, United States

... and 24 more locations